TWI573870B - Single-stranded nucleic acid molecules used to control gene expression (I) - Google Patents

Single-stranded nucleic acid molecules used to control gene expression (I) Download PDF

Info

Publication number
TWI573870B
TWI573870B TW104143857A TW104143857A TWI573870B TW I573870 B TWI573870 B TW I573870B TW 104143857 A TW104143857 A TW 104143857A TW 104143857 A TW104143857 A TW 104143857A TW I573870 B TWI573870 B TW I573870B
Authority
TW
Taiwan
Prior art keywords
region
aforementioned
bases
group
end side
Prior art date
Application number
TW104143857A
Other languages
English (en)
Chinese (zh)
Other versions
TW201627500A (zh
Inventor
Tadaaki Ohgi
Hirotake Hayashi
Hisao Shirohzu
Tomohiro Hamasaki
Akihiro Itoh
Hiroshi Suzuki
Original Assignee
Bonac Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bonac Corp filed Critical Bonac Corp
Publication of TW201627500A publication Critical patent/TW201627500A/zh
Application granted granted Critical
Publication of TWI573870B publication Critical patent/TWI573870B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW104143857A 2010-07-08 2011-07-08 Single-stranded nucleic acid molecules used to control gene expression (I) TWI573870B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2010156122 2010-07-08
JP2010174915 2010-08-03
JP2010230806 2010-10-13
JP2010230808 2010-10-13
JP2010269823 2010-12-02
JP2010269824 2010-12-02

Publications (2)

Publication Number Publication Date
TW201627500A TW201627500A (zh) 2016-08-01
TWI573870B true TWI573870B (zh) 2017-03-11

Family

ID=45441339

Family Applications (2)

Application Number Title Priority Date Filing Date
TW100124393A TWI527901B (zh) 2010-07-08 2011-07-08 A single stranded nucleic acid molecule used to control gene expression
TW104143857A TWI573870B (zh) 2010-07-08 2011-07-08 Single-stranded nucleic acid molecules used to control gene expression (I)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW100124393A TWI527901B (zh) 2010-07-08 2011-07-08 A single stranded nucleic acid molecule used to control gene expression

Country Status (17)

Country Link
EP (2) EP2431466B1 (enExample)
JP (3) JP4968811B2 (enExample)
KR (1) KR101849798B1 (enExample)
CN (2) CN104818276B (enExample)
AU (1) AU2011274854B2 (enExample)
BR (1) BR112013000481A2 (enExample)
CA (1) CA2804511C (enExample)
DK (2) DK2933333T3 (enExample)
ES (2) ES2670017T3 (enExample)
HU (2) HUE037500T2 (enExample)
MX (1) MX352568B (enExample)
NZ (2) NZ606232A (enExample)
PT (2) PT2431466E (enExample)
RU (1) RU2628311C2 (enExample)
SG (2) SG186899A1 (enExample)
TW (2) TWI527901B (enExample)
WO (1) WO2012005368A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691782B2 (en) 2010-08-03 2014-04-08 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
WO2013077446A1 (ja) * 2011-11-26 2013-05-30 株式会社ボナック 遺伝子発現制御のための一本鎖核酸分子
WO2013133393A1 (ja) * 2012-03-07 2013-09-12 学校法人東京医科大学 Ｖｅｇｆ遺伝子の発現抑制用一本鎖核酸分子
US20150105442A1 (en) 2012-03-29 2015-04-16 Aqua Therapeutics Co., Ltd. Nucleic Acid Molecule Capable of Inhibiting Expression of Periostin Gene, method for Inhibiting Expression of Periostin Gene, and Use of Said Nucleic Acid Molecule
EP2857513A4 (en) * 2012-05-26 2016-05-25 Bonac Corp Single-stranded nucleic acid molecule controlling the expression of a gene transporter
WO2015099122A1 (ja) 2013-12-26 2015-07-02 学校法人東京医科大学 遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途
RU2697094C2 (ru) 2013-12-27 2019-08-12 Бонак Корпорейшн ИСКУССТВЕННАЯ мкРНК С СООТВЕТСТВИЕМ ДЛЯ КОНТРОЛЯ ЭКСПРЕССИИ ГЕНОВ И ЕЕ ПРИМЕНЕНИЕ
EP3235906B1 (en) * 2014-12-15 2021-06-23 Bonac Corporation Single-stranded nucleic acid molecule for inhibiting tgf- beta 1 expression
CA2971827A1 (en) 2014-12-27 2016-06-30 Bonac Corporation Naturally occuring mirna for controlling gene expression, and use of same
CN108064289A (zh) 2015-03-27 2018-05-22 株式会社博纳克 具有递送功能和基因表达调控能力的单链核酸分子
PL3369816T3 (pl) 2015-10-30 2024-07-22 Toray Industries, Inc. KOMPOZYCJA STABILNIE ZAWIERAJĄCA CZĄSTECZKĘ JEDNONICIOWEGO KWASU NUKLEINOWEGO, KTÓRA HAMUJE EKSPRESJĘ GENU TGF-β1
HK1259060A1 (en) * 2015-12-29 2019-11-22 国立大学法人北海道大学 Single-stranded nucleic acid molecule inhibiting expression of prorenin gene or prorenin receptor gene, and use thereof
CA3013179A1 (en) 2016-01-30 2017-08-03 Bonac Corporation Artificial single guide rna and use thereof
EP3604528A4 (en) 2017-03-31 2021-01-13 Bonac Corporation CYCLIC NUCLEIC ACID MOLECULE HAVING A GENE EXPRESSION CONTROL FUNCTION
JPWO2018199338A1 (ja) * 2017-04-27 2020-03-12 国立大学法人広島大学 Ｂ型肝炎治療用核酸分子
EP3659609B1 (en) 2017-07-28 2024-05-08 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for fibrosis
IL273245B2 (en) * 2017-09-15 2025-03-01 Commw Scient Ind Res Org RNA molecules
US11298371B2 (en) 2017-10-11 2022-04-12 Nitto Denko Corporation Regulation of nucleic acid molecule expression
JPWO2019074110A1 (ja) * 2017-10-13 2020-12-24 株式会社ボナック 一本鎖核酸分子およびその製造方法
TWI830718B (zh) * 2018-02-09 2024-02-01 日商住友化學股份有限公司 核酸分子之製造方法
WO2019189722A1 (ja) 2018-03-30 2019-10-03 東レ株式会社 ヘアピン型一本鎖ｒｎａ分子の製造方法
WO2019189591A1 (ja) 2018-03-30 2019-10-03 住友化学株式会社 一本鎖ｒｎａの製造方法
WO2020071407A1 (ja) * 2018-10-02 2020-04-09 東レ株式会社 ヘアピン型一本鎖ｒｎａ分子の製造方法
WO2020152869A1 (ja) 2019-01-25 2020-07-30 杏林製薬株式会社 線維症治療剤
KR20220079832A (ko) 2019-10-11 2022-06-14 스미또모 가가꾸 가부시끼가이샤 핵산 올리고머의 제조 방법
WO2021153047A1 (ja) 2020-01-29 2021-08-05 住友化学株式会社 核酸オリゴマーの製造方法
KR20220133919A (ko) 2020-01-29 2022-10-05 스미또모 가가꾸 가부시끼가이샤 핵산 올리고머의 제조 방법
JP7613130B2 (ja) * 2020-03-25 2025-01-15 味の素株式会社 リガーゼ変異体
CN115335387A (zh) 2020-03-27 2022-11-11 住友化学株式会社 核酸寡聚物的制造方法
CN115867559A (zh) 2020-07-09 2023-03-28 住友化学株式会社 核酸寡聚物的制造方法
CN116209668A (zh) 2020-09-24 2023-06-02 住友化学株式会社 核酸寡聚物的制造方法
US20250051256A1 (en) 2021-09-28 2025-02-13 Sumitomo Chemical Company, Limited Production method for purified dichloroacetic acid
KR20240162536A (ko) 2022-03-23 2024-11-15 스미또모 가가꾸 가부시끼가이샤 핵산 올리고머의 제조 방법
JP7201190B1 (ja) 2022-06-03 2023-01-10 株式会社セツロテック 遺伝子改変動物由来の動物繊維
JPWO2024089953A1 (enExample) 2022-10-27 2024-05-02

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1669450A1 (en) * 2003-09-30 2006-06-14 AnGes MG, Inc. Staple type oligonucleotide and drug comprising the same
WO2009076321A2 (en) * 2007-12-07 2009-06-18 Halo-Bio Rnai Therapeutics Inc. Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5631148A (en) * 1994-04-22 1997-05-20 Chiron Corporation Ribozymes with product ejection by strand displacement
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
FR2790757B1 (fr) * 1999-03-09 2003-08-01 Bioalliance Pharma Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
TWI321054B (en) 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
WO2003072745A2 (en) * 2002-02-22 2003-09-04 Eshleman James R Antigene locks and therapeutic uses thereof
EP3222724B1 (en) * 2002-08-05 2018-10-31 Silence Therapeutics GmbH Further novel forms of interfering rna molecules
US20040058886A1 (en) * 2002-08-08 2004-03-25 Dharmacon, Inc. Short interfering RNAs having a hairpin structure containing a non-nucleotide loop
AU2005327517B2 (en) * 2004-06-30 2011-05-26 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a non-phosphate backbone linkage
WO2006074108A2 (en) * 2004-12-30 2006-07-13 Hauser Todd M Compositions and methods for modulating gene expression using self-protected oligonucleotides
KR100848666B1 (ko) * 2006-03-17 2008-07-28 (주)바이오니아 NF-k B의 발현을 억제하는 s i RNA
JP5296328B2 (ja) 2007-05-09 2013-09-25 独立行政法人理化学研究所 １本鎖環状ｒｎａおよびその製造方法
WO2009074076A1 (en) * 2007-11-29 2009-06-18 Suzhou Ribo Life Science Co., Ltd A complex molecule interfering the expression of target genes and its preparing methods
WO2009102081A1 (ja) * 2008-02-15 2009-08-20 Riken 環状１本鎖核酸複合体およびその製造方法
JP5187580B2 (ja) 2008-12-26 2013-04-24 丸紅建材リース株式会社 掘削機の泥土飛散防止装置
JP2010174915A (ja) 2009-01-27 2010-08-12 Toyota Motor Corp 高圧ガスタンク
JP5233790B2 (ja) 2009-03-26 2013-07-10 船井電機株式会社 液晶モジュール
JP5449815B2 (ja) 2009-03-26 2014-03-19 住友化学株式会社 偏光板の製造方法
JP2010269823A (ja) 2009-05-21 2010-12-02 British American Tobacco Japan Kk 喫煙品用容器
JP4885255B2 (ja) 2009-05-21 2012-02-29 株式会社エフピコ 包装用容器

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1669450A1 (en) * 2003-09-30 2006-06-14 AnGes MG, Inc. Staple type oligonucleotide and drug comprising the same
WO2009076321A2 (en) * 2007-12-07 2009-06-18 Halo-Bio Rnai Therapeutics Inc. Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides

Also Published As

Publication number Publication date
JP5804642B2 (ja) 2015-11-04
MX2013000315A (es) 2013-05-01
JP2012130342A (ja) 2012-07-12
NZ704812A (en) 2017-01-27
ES2670017T3 (es) 2018-05-29
EP2431466A4 (en) 2012-04-25
AU2011274854A1 (en) 2013-02-14
TW201217523A (en) 2012-05-01
AU2011274854B2 (en) 2015-04-16
PT2933333T (pt) 2018-04-24
SG196779A1 (en) 2014-02-13
EP2431466B1 (en) 2015-10-07
JP6162182B2 (ja) 2017-07-12
KR20130090792A (ko) 2013-08-14
DK2431466T3 (en) 2016-01-11
KR101849798B1 (ko) 2018-04-17
DK2933333T3 (en) 2018-04-30
JPWO2012005368A1 (ja) 2013-09-05
BR112013000481A2 (pt) 2019-10-15
HK1181423A1 (zh) 2013-11-08
CN102918156A (zh) 2013-02-06
JP2015231381A (ja) 2015-12-24
EP2933333A1 (en) 2015-10-21
HUE037500T2 (hu) 2018-08-28
EP2933333B1 (en) 2018-02-21
CN102918156B (zh) 2015-11-25
ES2550487T3 (es) 2015-11-10
CA2804511A1 (en) 2012-01-12
PT2431466E (pt) 2016-01-08
JP4968811B2 (ja) 2012-07-04
TWI527901B (zh) 2016-04-01
NZ606232A (en) 2015-06-26
SG186899A1 (en) 2013-02-28
CN104818276A (zh) 2015-08-05
CN104818276B (zh) 2020-12-11
WO2012005368A1 (ja) 2012-01-12
HUE026520T2 (en) 2016-06-28
RU2628311C2 (ru) 2017-08-15
CA2804511C (en) 2021-07-06
MX352568B (es) 2017-11-29
RU2013105329A (ru) 2014-08-20
TW201627500A (zh) 2016-08-01
EP2431466A1 (en) 2012-03-21

Similar Documents

Publication Publication Date Title
TWI573870B (zh) Single-stranded nucleic acid molecules used to control gene expression (I)
TWI515294B (zh) A single stranded nucleic acid molecule having a nitrogen-containing lipid ring skeleton
US8785121B2 (en) Single-stranded nucleic acid molecule for controlling gene expression
WO2013077446A1 (ja) 遺伝子発現制御のための一本鎖核酸分子
HK1181423B (en) Single-strand nucleic acid molecule for controlling gene expression
HK1200460B (en) Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton